Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Arbutus Biopharma Cp (ABUS)

Arbutus Biopharma Cp (ABUS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 431,350
  • Shares Outstanding, K 99,161
  • Annual Sales, $ 6,910 K
  • Annual Income, $ -63,750 K
  • 60-Month Beta 2.90
  • Price/Sales 61.81
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade ABUS with:

Options Overview

Details
  • Implied Volatility 147.06%
  • Historical Volatility 67.20%
  • IV Percentile 46%
  • IV Rank 40.12%
  • IV High 275.22% on 08/24/21
  • IV Low 61.18% on 05/13/21
  • Put/Call Vol Ratio 0.31
  • Today's Volume 4,582
  • Volume Avg (30-Day) 4,387
  • Put/Call OI Ratio 0.11
  • Today's Open Interest 37,972
  • Open Int (30-Day) 44,911

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/21
See More
  • Average Estimate -0.24
  • Number of Estimates 2
  • High Estimate -0.23
  • Low Estimate -0.25
  • Prior Year -0.27
  • Growth Rate Est. (year over year) +11.11%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.98 +44.97%
on 08/23/21
4.67 -7.49%
on 09/10/21
+1.40 (+47.95%)
since 08/20/21
3-Month
2.54 +70.41%
on 07/15/21
4.67 -7.49%
on 09/10/21
+1.07 (+32.92%)
since 06/18/21
52-Week
2.43 +77.78%
on 05/13/21
5.87 -26.41%
on 12/15/20
+1.18 (+37.58%)
since 09/18/20

Most Recent Stories

More News
RNAi Technology Market Size, Share, Value, Competitive landscape, Industry outlook and Future Forecast till 2027

Research Nester released a report titled ": Global Demand Analysis & Opportunity Outlook 2027" which delivers detailed overview of the global RNAi technology market in terms of market segmentation by therapy...

ALNY : 183.92 (-3.37%)
DRNA : 20.56 (-4.86%)
ARWR : 62.45 (-3.82%)
IONS : 36.65 (-1.50%)
ABUS : 4.30 (-1.15%)
BLT : 10.00 (+0.20%)
SLN.LN : 552.000 (+1.47%)
Arbutus to Participate in Upcoming Investor Conferences

Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on discovering, developing and commercializing a cure for people with chronic hepatitis B virus...

ABUS : 4.30 (-1.15%)
Is the Options Market Predicting a Spike in Arbutus Biopharma (ABUS) Stock?

Investors need to pay close attention to Arbutus Biopharma (ABUS) stock based on the movements in the options market lately.

ABUS : 4.30 (-1.15%)
2021 Pipeline Insights on Chronic Hepatitis B Virus Infections - Featuring Arbutus Biopharma, Enyo Pharma and Gilead Sciences Among Others - ResearchAndMarkets.com

The "Chronic Hepatitis B Virus Infection - Pipeline Insight, 2021" clinical trials has been added to ResearchAndMarkets.com's offering.

ABUS : 4.30 (-1.15%)
GILD : 70.56 (-1.47%)
Arbutus Biopharma (ABUS) Reports Q2 Loss, Tops Revenue Estimates

Arbutus (ABUS) delivered earnings and revenue surprises of -9.52% and 12.35%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

ABUS : 4.30 (-1.15%)
Arbutus: Q2 Earnings Snapshot

WARMINSTER, Pa. (AP) _ Arbutus Biopharma Corp. (ABUS) on Thursday reported a loss of $19.4 million in its second quarter.

ABUS : 4.30 (-1.15%)
Arbutus Reports Second Quarter 2021 Financial Results and Provides Corporate Update

New data on AB-729, Arbutus' proprietary subcutaneously delivered RNAi agent, highlighted in four abstracts at the EASL International Liver Congress(TM); all AB-729 abstracts selected for best of ILC(TM)...

ABUS : 4.30 (-1.15%)
Arbutus to Present at Wedbush PacGrow Healthcare Virtual Conference

Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on discovering, developing and commercializing a cure for people with chronic hepatitis B virus...

ABUS : 4.30 (-1.15%)
Arbutus to Report Second Quarter 2021 Financial Results and Provide Corporate Update

Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on discovering, developing and commercializing a cure for people with chronic hepatitis B virus...

ABUS : 4.30 (-1.15%)
Arbutus Receives Authorization to Proceed with an Investigational New Drug Application (IND) for AB-729, its Proprietary Subcutaneously-Delivered RNAi Agent

Phase 2a trial to investigate the safety and anti-viral activity of AB-729 in combination with ongoing nucleos(t)ide analog (NA) therapy and short courses of Peg-IFNα-2a in subjects with chronic hepatitis...

ABUS : 4.30 (-1.15%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Average short term outlook on maintaining the current direction.

See More Share

Business Summary

Arbutus Biopharma Corporation is a biopharmaceutical company which is focused on discovering, developing and commercializing a portfolio of drug candidates for chronic hepatitis B infection. The Company's products include TKM-HBV, Cyclophilin Inhibitor-OCB-030, TLR9 Agonist (CYT-003), Capsid Assembly...

See More

Key Turning Points

3rd Resistance Point 4.65
2nd Resistance Point 4.51
1st Resistance Point 4.43
Last Price 4.30
1st Support Level 4.21
2nd Support Level 4.07
3rd Support Level 3.99

See More

52-Week High 5.87
Fibonacci 61.8% 4.56
Last Price 4.30
Fibonacci 50% 4.15
Fibonacci 38.2% 3.74
52-Week Low 2.43

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar